Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.78 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | NCF1 | P14598 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | NPY1R | P25929 | 1/20 | 0.44 |
| ▸ | NPY2R | P49146 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25947756 | 0.88 | ALDH1A1 (1.00) | KDM4EALDH1A1GFERL3MBTL1KMT2A | |
| SCHEMBL12000237 | 0.86 | ALDH1A1 (0.59) | KDM4EALDH1A1GFERHCAR2EGFR | |
| SCHEMBL28827744 | 0.86 | ALDH1A1 (0.77) | KDM4EALDH1A1GFERHCAR2EGFR | |
| SCHEMBL11971653 | 0.80 | KDM4E (0.51) | KDM4EALDH1A1L3MBTL1KMT2AHPGD | |
| SCHEMBL13227175 | 0.80 | ALDH1A1 (0.52) | KDM4EALDH1A1GFERHCAR2L3MBTL1 | |
| SCHEMBL11971661 | 0.79 | PDE10A (0.54) | KDM4EALDH1A1HPGDF2GLA | |
| SCHEMBL14617053 | 0.79 | MAPT (0.57) | KDM4EALDH1A1KMT2ASMN1; SMN2POLB | |
| SCHEMBL3220280 | 0.79 | ALDH1A1 (0.51) | KDM4EALDH1A1GFERHCAR2EGFR | |
| SCHEMBL1289546 | 0.78 | NCF1 (0.51) | KDM4EALDH1A1GFEREGFRL3MBTL1 | |
| SCHEMBL16788278 | 0.77 | CYP1A1 (0.52) | KDM4EALDH1A1GFEREGFRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114957112-B | (2-chloroquinoline-3-yl) methyl (N-p-fluorophenyl) carbamate and preparation method and application thereof | 渤海大学 | 2023-01-17 | — | — | CN | disclosed |
| CN-114957112-A | (2-chloroquinoline-3-yl) methyl (N-p-fluorophenyl) carbamate and preparation method and application thereof | 渤海大学 | 2022-08-30 | — | — | CN | disclosed |
| US-8399483-B2 | Quinoxaline and quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2013-03-19 | — | — | US | disclosed |
| US-8273885-B2 | Fluoroboron compound having aromatic ring or salt thereof, and method for producing compound having cyclic ether-fused aromatic ring using the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| US-8273885-B2 | Fluoroboron compound having aromatic ring or salt thereof, and method for producing compound having cyclic ether-fused aromatic ring using the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| US-8273885-B2 | Fluoroboron compound having aromatic ring or salt thereof, and method for producing compound having cyclic ether-fused aromatic ring using the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA, S.A. (BE) | 2011-05-05 | — | — | US | disclosed |
| EP-2231641-A2 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2010-09-29 | — | — | EP | disclosed |
| US-20100056788-A1 | FLUOROBORON COMPOUND HAVING AROMATIC RING OR SALT THEREOF, AND METHOD FOR PRODUCING COMPOUND HAVING CYCLIC ETHER-FUSED AROMATIC RING USING THE SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056788-A1 | FLUOROBORON COMPOUND HAVING AROMATIC RING OR SALT THEREOF, AND METHOD FOR PRODUCING COMPOUND HAVING CYCLIC ETHER-FUSED AROMATIC RING USING THE SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056788-A1 | FLUOROBORON COMPOUND HAVING AROMATIC RING OR SALT THEREOF, AND METHOD FOR PRODUCING COMPOUND HAVING CYCLIC ETHER-FUSED AROMATIC RING USING THE SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| WO-2009081105-A2 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-07-02 | — | — | WO | disclosed |
| EP-2062901-A1 | FLUOROBORON COMPOUND HAVING AROMATIC RING OR SALT THEREOF, AND PROCESS FOR PRODUCTION OF COMPOUND HAVING CYCLIC ETHER-FUSED AROMATIC RING BY USING THE SAME | Eisai R&D Management Co., Ltd. (JP) | 2009-05-27 | — | — | EP | disclosed |
| EP-2062901-A1 | FLUOROBORON COMPOUND HAVING AROMATIC RING OR SALT THEREOF, AND PROCESS FOR PRODUCTION OF COMPOUND HAVING CYCLIC ETHER-FUSED AROMATIC RING BY USING THE SAME | Eisai R&D Management Co., Ltd. (JP) | 2009-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056788-A1 | FLUOROBORON COMPOUND HAVING AROMATIC RING OR SALT THEREOF, AND METHOD FOR PRODUCING COMPOUND HAVING CYCLIC ETHER-FUSED AROMATIC RING USING THE SAME | FLI1, AFF1, MLLT3 | KDM4E 249/4885ALDH1A1 2353/4885GFER 2075/4885 |
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | PDXK, PDPK1, PIKFYVE | KDM4E 2230/4885ALDH1A1 4276/4885GFER 3610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.